This article was originally published in The Gray Sheet
Forms alliance with OPTIMEDx to develop optical imaging agents for detection and localization of cancer cells. Seattle-based OPTIMEDx is developing a light-based imaging technology "designed to improve the detection and definition of certain cancer cells at an early stage," the companies said. Mallinckrodt will make an equity investment in OPTIMEDx, milestone payments, and product royalties. The company gains exclusive rights "to develop optical imaging agents for mammography" and non-exclusive rights to develop other cancer imaging agents
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.